| Matthew Baldwin Deegan, PT | |
|
141 E Main St, Huntington, NY 11743-2852 | |
| (631) 421-9111 | |
| (631) 421-1622 |
| Full Name | Matthew Baldwin Deegan |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 25 Years |
| Location | 141 E Main St, Huntington, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659462281 | NPI | - | NPPES |
| 02372269 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 021149 (New York) | Primary |
| Provider Name | Huntington Physical Therapy |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1962619395 PECOS PAC ID: 1355231994 Enrollment ID: O20040317001533 |
News Archive
A drug developed 50 years ago and abandoned because it was considered to be too toxic has gained a second life in an international clinical trial. Research led by scientists at Dana-Farber Cancer Institute showed the drug and a potentiating agent lengthened the lives of patients with metastatic colorectal cancer, all of whom had exhausted available standard treatments.
Sanofi announced today data from four studies of its once-daily GLP-1 receptor agonist Lyxumia that is in Phase III clinical development, including data that demonstrates positive results in type 2 diabetes patients not at goal on oral therapies or with basal insulin.
Member states at the 65th session of the World Health Assembly, which concluded last week, "agreed to adopt a global target of a 25 percent reduction in premature mortality from non-communicable diseases [NCDs] such as cardiovascular disease, cancer, diabetes and chronic respiratory diseases by 2025."
Although there is no one established universal cause of cancer, genetic changes are central to its development. The accumulation of spontaneous genetic changes, or mutations, that occur when cells divide can be hastened by exposure to carcinogens such as cigarette smoke (lung cancer) and infectious agents such as the papillomavirus (cervical cancer).
EGR4 is a master gene responsible for fertility in cryptorchidism. Is gene therapy going to replace surgery?
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew Baldwin Deegan, PT 141 E Main St, Huntington, NY 11743-2852 Ph: (631) 421-9111 | Matthew Baldwin Deegan, PT 141 E Main St, Huntington, NY 11743-2852 Ph: (631) 421-9111 |
News Archive
A drug developed 50 years ago and abandoned because it was considered to be too toxic has gained a second life in an international clinical trial. Research led by scientists at Dana-Farber Cancer Institute showed the drug and a potentiating agent lengthened the lives of patients with metastatic colorectal cancer, all of whom had exhausted available standard treatments.
Sanofi announced today data from four studies of its once-daily GLP-1 receptor agonist Lyxumia that is in Phase III clinical development, including data that demonstrates positive results in type 2 diabetes patients not at goal on oral therapies or with basal insulin.
Member states at the 65th session of the World Health Assembly, which concluded last week, "agreed to adopt a global target of a 25 percent reduction in premature mortality from non-communicable diseases [NCDs] such as cardiovascular disease, cancer, diabetes and chronic respiratory diseases by 2025."
Although there is no one established universal cause of cancer, genetic changes are central to its development. The accumulation of spontaneous genetic changes, or mutations, that occur when cells divide can be hastened by exposure to carcinogens such as cigarette smoke (lung cancer) and infectious agents such as the papillomavirus (cervical cancer).
EGR4 is a master gene responsible for fertility in cryptorchidism. Is gene therapy going to replace surgery?
› Verified 3 days ago
John W Titcomb, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1206 E Jericho Tpke Unit A, Huntington, NY 11743 Phone: 631-549-0749 Fax: 631-549-1562 | |
Mr. Ward Tucker Iii, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 141 E Main St, Huntington, NY 11743 Phone: 631-421-9111 | |
Melanie Carminati, Physical Therapist Medicare: Medicare Enrolled Practice Location: 13 South Ln, Huntington, NY 11743 Phone: 631-219-9194 | |
Steven Browning, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 221 E Main St, Huntington, NY 11743 Phone: 631-533-2888 Fax: 631-638-5584 | |
Zinnia Dodson, Physical Therapist Medicare: Medicare Enrolled Practice Location: 221 E Main St, Huntington, NY 11743 Phone: 631-533-2888 | |
Mrs. Stephanie Foley, MS PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 467 New York Ave, Huntington, NY 11743 Phone: 631-424-1100 Fax: 631-424-1105 | |
Norbert Jack Ryglewicz, MSPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 232 E Main St, Huntington, NY 11743 Phone: 516-639-1819 |